IGF-1 LR3

IGF-1 LR3 Peptide Vials

It is advised to mix two vials of 100 mcg with acetic acid before using them in a laboratory or experimental setting.

Introduction

IGF-1 LR3 Vial is a research product featuring Insulin-Like Growth Factor 1 Long R3 (IGF-1 LR3), an extended variant of IGF-1 renowned for its heightened bioactivity. These vials are expressly crafted for precise and consistent utilization in research applications, adhering to rigorous quality control measures to ensure reliability.

Key Characteristics

IGF-1 LR3 Vials are distinguished by the inclusion of the extended variant of Insulin-Like Growth Factor 1 (IGF-1 LR3), renowned for its advanced bioactivity, ensuring increased efficacy in research applications. Meticulously formulated for precision, these vials provide researchers with a consistent source of IGF-1 LR3, facilitating accurate and reproducible results across experiments. Manufactured under stringent quality control measures, the product upholds reliability and integrity, meeting the high standards necessary for scientific research and experimentation.

Research Applications

IGF-1 LR3 vials find application in diverse scientific inquiries, specifically in studies focused on cellular growth, metabolism, and muscle-related conditions.

Research Benefits

May Promote Cell Division

Preliminary research indicates that IGF-1 LR3 may have the capacity to promote cell division, making it a compelling subject for investigations into cellular growth and regeneration.

May Boost Fat Metabolism and Support Diabetes Research

Emerging studies propose that IGF-1 LR3 might play a role in enhancing fat metabolism, presenting a potential avenue for research in the realm of diabetes management. This warrants further scrutiny in controlled research settings.

May Impair Myostatin

Early evidence suggests that IGF-1 LR3 may have the potential to impair myostatin, a key regulator of muscle growth. This opens doors for research into conditions associated with muscle development and wasting.

Summary

IGF-1 LR3 vials stand as a valuable asset for scientific researchers investigating the potential benefits of IGF-1 LR3 in controlled laboratory environments. These vials are intended exclusively for research purposes, and researchers are urged to explore and contribute to the understanding of IGF-1 LR3’s impact on cellular biology, metabolism, and muscle-related conditions.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer satisfaction is our top priority. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at support@bc9.co.

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. Not for veterinary or human use.

References

1. Assefa B, Mahmoud AM, Pfeiffer AFH, Birkenfeld AL, Spranger J, Arafat AM. Insulin-Like Growth Factor (IGF) Binding Protein-2, Independently of IGF-1, Induces GLUT-4 Translocation and Glucose Uptake in 3T3-L1 Adipocytes. Oxid Med Cell Longev. 2017;2017:3035184. doi: 10.1155/2017/3035184. Epub 2017 Dec 20. PMID: 29422987; PMCID: PMC5750484. [Read More]
2. Carroll PV, Christ ER, Umpleby AM, Gowrie I, Jackson N, Bowes SB, Hovorka R, Croos P, Sönksen PH, Russell-Jones DL. IGF-I treatment in adults with type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp. Diabetes. 2000 May;49(5):789-96. doi: 10.2337/diabetes.49.5.789. PMID: 10905488. [Read More]
3. Lang CH, Frost RA, Svanberg E, Vary TC. IGF-I/IGFBP-3 ameliorates alterations in protein synthesis, eIF4E availability, and myostatin in alcohol-fed rats. Am J Physiol Endocrinol Metab. 2004 Jun;286(6):E916-26. doi: 10.1152/ajpendo.00554.2003. Epub 2004 Jan 28. PMID: 14749210. [Read More]